<DOC>
	<DOCNO>NCT01927965</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) Minnelide™ establish dose Minnelide™ recommend future phase 2 protocol</brief_summary>
	<brief_title>Study Minnelide™ Patients With Advanced GI Tumors</brief_title>
	<detailed_description>This Phase 1 , open label , multicenter , dose-escalation study safety , pharmacokinetics , pharmacodynamics Minnelide™ Minnelide™ give single agent intravenously 30-minute infusion daily x 21 day follow 7-day rest period . One cycle equal 28 day . Dose escalation follow modify Fibonacci design .</detailed_description>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : 1 . Histologically cytologically confirm gastrointestinal ( GI ) carcinoma , progressed standard therapy ( surgery , radiotherapy , endocrine therapy , chemotherapy ) , effective therapy available patient candidate intolerant therapy . 2 . Have one metastatic tumor measurable CT scan locally advanced measurable disease clearly progress prior treatment per RECIST criterion . 3 . Male female patient least 18 year age 4 . Laboratory data specify : Hematology : ANC &gt; 1500 cells/mm3 , platelet count &gt; 150,000 cells/mm3 Hemoglobin &gt; 9 g/dL Hepatic : Direct bilirubin ≤1.5 X ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 X ULN . For patient know liver metastasis liver neoplasms , ALT AST ≤ 5.0 X ULN allow Renal : serum creatinine WNL calculate creatinine clearance ≥ 50 mL/min/1.73m2 patient creatinine level institutional normal Urinalysis : No clinically significant abnormality Coagulation : INR within normal limit , PTT within normal limit 5 . Estimated life expectancy least 3 month 6 . Karnofsky Performance ≥ 70 % 7 . A negative serum pregnancy test ( female ) 8 . For men woman childproducing potential willingness employ appropriate contraceptive method ( include abstinence ) study . 9 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 1 . Women pregnant nursing . NOTE : Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 2 . New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia , evidence ischemia ECG . 3 . Baseline QTc exceed 450 msec ( 470 msec female ) use Bazetts formula and/or patient receive class 1A class III antiarrythmic agent . 4 . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . 5 . Treatment radiotherapy , chemotherapy investigational therapy within 1 month ( 5 half lifes cytotoxics ) prior study entry ( 6 week nitrosoureas Mitomycin C ) . 6 . Known HIV , Hepatitis A , B Hepatitis C infection 7 . Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion investigator and/or sponsor . 8 . Participation concurrent study investigational agent device . 9 . Unwillingness inability comply procedure require protocol . 10 . Any condition include limited major comorbidities , opinion investigator would render patient ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>gastrointestinal tract</keyword>
	<keyword>GI tract</keyword>
	<keyword>advanced gastrointestinal tumor</keyword>
	<keyword>gastrointestinal tumor</keyword>
	<keyword>GI tumor</keyword>
	<keyword>biliary</keyword>
	<keyword>gallbladder ,</keyword>
	<keyword>colorectal ,</keyword>
	<keyword>gastric ,</keyword>
	<keyword>hepatocellular</keyword>
	<keyword>esophageal</keyword>
	<keyword>pancreatic</keyword>
</DOC>